Details of the Drug

General Information of Drug (ID: DM0ZIT2)

Drug Name
PTX-200
Synonyms Plant-derived antiparkinsonian, Phytrix
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Parkinson disease 8A00.0 Phase 2 [2]
Acute myeloid leukaemia 2A60 Phase 1 [1]
Ovarian cancer 2C73 Phase 1 [1]
Cross-matching ID
TTD ID
D0X7CV
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
RAC-alpha serine/threonine-protein kinase (AKT1) DTT AKT1 2.63E-29 0.65 1.45
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 PTX-200 Phase 1b/2 clinical trial update. Prescient Therapeutics. 26 August 2015.